Clinical Trial Update: A Study of SAR444245 With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma (Master Protocol) [Pegathor Lymphoma 205] [Phase 2]

View source ↗

Summary

A Phase 2 master protocol evaluating SAR-444245 for relapsed or refractory B-cell lymphoma was terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Hodgkin Lymphoma Classical Type

Drugs mentioned

• SAR-444245

Snippet

Sponsor: Sanofi | Conditions: Classic Hodgkin Lymphoma, Diffuse Large B-cell Lymphoma | Phase 2 | Status: TERMINATED | Results posted: 2025-10-02